tivity among organs or body sites may vary. 1 Phenacetin is p r e d o m i n a n t l y m e t a b o l i z e d to an active d r u g , acetaminophen (paracetamol). Aspirin and phenacetin are combined in reduced amounts in marketed products, hence the combination would not be expected to be superior to an optimal amount of either when given singly. Several studies, including that of Moertel et al., indicate that, in the doses used, APC is no more effective than aspirin or acetaminophen alone. 2 These facts are sufficient reason to remove all APC combinations from drug formularies.
Long-term use of analgesics may produce life-threatening consequences. Analgesic mixtures, particularly those containing phenacetin, have been shown to cause analgesic nephropathy (often ending in renal failure) and renal pelvic and ureteral (uroepithelial) tumors. 3 , 4 Analgesic nephropathy is clinically characterized by findings of interstitial nephritis, renal papillary necrosis, hypertension, impaired urinary concentrating ability unresponsive to vasopressin, and increased serum creatinine with decreased renal clearance. As a result, many victims may need chronic dialysis due to end-stage renal disease. However, clinical experience demonstrates than when analgesic mixtures are discontinued in patients with analgesic nephropathy, renal function usually stabilizes.
There is understandable confusion over which drug(s) are responsible for analgesic nephropathy. In 1965, Prescott showed that aspirin, phenacetin, acetaminophen, and caffeine each significantly increased urinary renal tubular cell counts. 5 Clinical and experimental evidence points to nephrotoxic changes with doses of aspirin 4 and caffeine 6 individually. Recent reviews indicate that renal papillary necrosis is more readily induced by mixtures of analgesics that include phenacetin or acetaminophen, than by aspirin, phenacetin, or acetaminophen alone. This necrosis may be due to ischemia; medullary blood flow is reduced as a result of inhibition of prostaglandin synthesis. Agents such as indomethacin and ibuprofen may also cause similar effects. 4 Considerable epidemiologic evidence exists to demonstrate the benefit of removing phenacetin from analgesic mixtures. Sweden restricted phenacetin use to single entity prescription status in 1961, and the overall incidence of mortality due to renal failure" and papillary necrosis at autopsy 8 decreased in the following years. Experience in Canada 9 and Western Scotland 10 supports the conclusion that phenacetin removal from analgesic powders was beneficial to public health. A controlled, prospective study in Switzerland demonstrated the danger of phenacetin-containing mixtures. 3 Evidence also indicts analgesic mixtures of aspirin, caffeine, salicylamide, and other agents. 4 Thus, the issue is not as simple as eliminating phenacetin.
Some authors have brought attention to the need for public education and warnings on medication containers. Others have reviewed hundreds of articles and concluded that more research is needed or that the subject is still controversial. Meanwhile, Goody's Headache Powder®, Darvon Compound®, Fiorinal®, Percodan®, and other mixtures continue to be sold in food stores and drug stores, or are prescribed by physicians. Burroughs Wellcome Co. is to be commended for recently removing phenacetin from Empirin Compound®. Great Britain has already taken a step by enacting, in March, 1980, a total ban on phenacetin-containing analgesic mixtures." The FDA has sufficient therapeutic and toxicologie justification to also ban phenacetin in the U.S. However, under no circumstances should acetaminophen be added to salicylate as a replacement for phenacetin. Therapeutic data also do not support the addition of caffeine to analgesics. 2 Finally, the FTC should require every public drug adver- ment that looks to the future and alerts readers to immense changes we can expect. "In the future," it states, "incredibly expensive technology could enable a few people to live for 200 years or more. Who will be chosen? And, who will choose?" Within the next few decades, much longer life spans could become possible. Based on research projects now under way, transplantation may assume much more importance; it is likely that, some day, all organs may be amenable to transplantation. Deactivated genes may one day be regenerated and be able to renew cell tissue. Dietary restrictions may lead to increased longevity and a decreased incidence of cancer. Prosthetics and cyborgs may be combined to form machine-human combinations. And lowering body temperatures may increase life spans. This may be the future.
In the meantime, however, growing old in America is difficult for many people. In 1976, 17.6 percent of women and 15 percent of men over 65 years of age lived on or below the poverty level. 1 Elderly black women were even more hard-pressed. In some of America's larger metropolitan areas, as much as 25 percent of the population are classified as "gray area" people: those who cannot meet the needs of daily living but have "too much" income to qualify for assistance. 2 It has been estimated that as many as two to three million people in this countryhomebound, bedridden, or without transportation -are medically underserved or not served at all. Home health care is still mainly a concept, but one that ought to be vigorously pursued and developed as a viable and important part of chronic care. 3 " 5 As pharmacists, we must expect to see an increasingly older patient population, and one that will change in its characteristics. The fastest-growing segment of the U.S. population consists of women 65 years of age and older. In 1977, there were 13.9 million women and 9.5 million men in that age group. It is estimated that by the year 2035, there will be 33.4 million women and 22.4 million men over 65 years of age. Today, most women over 65 are widows, and only 16 000 of them remarry each year. Of women who are over 75 years of age, almost 70 percent are widows. 6 They have little chance of remarrying. What do these facts suggest in terms of pharmaceutical patientcare services to the elderly?· Most notably, they mean that pharmacists must become much more involved than ever before with the patient's social support structure. If the patient is not aware of all the support services available from various agencies, the pharmacists should be able to intervene and direct her. In short, the pharmacist must b e a health-care provider, able to give information about matters that may not, at the moment, be considered within the realm of "pharmacy."
But to be a provider of total patient care, the pharmacist must also be aware of the socioeconomic aspects with which each patient must cope.
Total health care implies concern for the patient and her family, not only in terms of drug therapy, but in terms of the patient's continuum of life. Will a particular drug therapy interfere with her life style? Must the environ-
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